Clinical Trial: First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362888) titled 'First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors' on Jan. 15.

Brief Summary: The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Solid Tumors (Phase 1)

Intervention: DRUG: ADCE-B05

Biological: Antibody-drug conjugate (ADC)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Adcendo ApS

Disclaimer: Curated by HT Syndication....